A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.

NCT04231682 | Withdrawn Phase 2 FDA Drug

• 1 other identifier: IRB-2020-300
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Organ transplant recipients are known to suffer from bone loss and subsequent fractures after the transplant operation with the most rapid bone loss occurring within the first 3-12 months. Guidelines for prevention and treatment of this serious complication are only written by individual medical societies interested in each organ (separate kidney from liver or heart transplants management) and they are based on studies done with limited medications choices. The majority of studies are done with the use of bisphosphonates, and there are very limited, or no data, on the effect of other medications used for Osteoporosis, including the use of denosumab. This study will focus on the evaluation of the efficacy and safety of denosumab 60mg use early (within first 3 months) after Liver Transplantation in the management of bone loss and prevention of fragility fractures. Different tests will be used to study the effect of the medication on the skeleton, including imaging studies as well as specific labwork.

Conditions

Osteoporosis

Outcome Measures

Primary Outcomes (1)

• The percentage changes in bone mass calculated by DEXA scan t-score of Lumbar Spine in the intervention and control groups at 12 months.

  12 months

Secondary Outcomes (6)

• The percentage changes in bone mass calculated by DEXA scan t-score of Femoral Neck, Total Hip and Wrist in the intervention and control groups at 12 months.

  12 months

• The percentage changes in bone mass calculated by DEXA scan t-score of Lumbar Spine, Femoral Neck, Total Hip and Wrist in the intervention and control groups at 24 months.

  24 months

• The vertebral and non-vertebral fracture incidence at 12 and 24 months.

  12 and 24 months

• The percentage changes of biochemical markers of variables of bone turnover (BSAP, CTX and PINP) from baseline to 6, 12, 18 and 24 months after 1st medication administration.

  6, 12, 18 and 24 months

• The percentage changes of creatinine, Calcium, Magnesium, Phosphorus, PTH intact and 25-Vit D levels from baseline to 6, 12, 18 and 24 months after the 1st medication administration.

  6, 12, 18 and 24 months

Study Arms (2)

Denosumab receiving group.

EXPERIMENTAL

Patients in this arm will receive denosumab injection 60 mg subcutaneously every 6 months. (A total of 4 injections)

Drug: Denosumab Injection

Placebo receiving group.

PLACEBO COMPARATOR

Patients in this arm will receive Placebo injection subcutaneously every 6 months. (A total of 4 injections)

Drug: Placebos

Interventions

Denosumab Injection DRUG

Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.

Denosumab receiving group.

Placebos DRUG

Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.

Placebo receiving group.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \>=18 years old
• First-time Liver transplant Recipients
• All men, postmenopausal women and women with history of hysterectomy or tubal ligation
• Patients who have not been treated with medications for Osteoporosis within the past 12 months before the liver transplant
• Patients able and agreeable to follow up at out Institution for the duration of the study
• Patients hospitalized for less than 45 consecutive days after the liver transplant surgery
• Patients with GFR\>30ml/min (calculated by Cockcroft-Gault equation, see Table 3 for details)
• Patients with corrected Calcium \>= 8.5
• Patients with PTH intact levels WNL (as per lab values)
• Patients with vit D\>=20; NOTE: patients with vit D \<20 will be treated with high dose Ergocalciferol 50,000 units daily and rechecked in 2 weeks
• Patients with t-score \>=-3.5 at all sites checked by DEXA scan
• Patients agree to sign an informed consent form to be in the study
• Can be treated with denosumab or placebo within 3 months from the liver transplant date

You may not qualify if:

• Patients with previous transplants
• Patients that are getting 2 simultaneous transplants, like combined kidney and liver transplants
• Age \< 18 year old
• Patients hospitalized for over 45 days after the liver transplant surgery
• Patients with GFR\< 30ml/min
• Patients with hypocalcemia defined as corrected calcium \< 8.5
• Patients with extensive dental problems, previous hx of Osteonecrosis of the jaw (ONJ) and/or high risk for developing ONJ
• Patients with current Hyperthyroidism
• Patients with current Primary Hyperparathyroidism defined by the combination of elevated calcium and PTH intact levels
• Patients with severe Osteoporosis as defined by t-score \<-3.5 at any site shown by DEXA scan
• Women of reproductive age without history of tubal ligation or hysterectomy
• Patients who cannot read or understand the Informed Consent Document or study instructions
• Patients with diagnosis of dementia, or otherwise unable to give informed consent
• Patients unable to follow up in our Institution for the duration of the study

Sponsors & Collaborators

• Albert Einstein Healthcare Network: lead
• Amgen: collaborator

MeSH Terms

Conditions

Osteoporosis

Interventions

Denosumab

Condition Hierarchy (Ancestors)

Bone Diseases, Metabolic; Bone Diseases; Musculoskeletal Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Catherine Anastasopoulou, MD, PhD

  Einstein Medical Center Philadelphia.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Attending Physician, Diabetes and Endocrinology.

Study Record Dates

• First Submitted: January 3, 2020
• First Posted: January 18, 2020
• Study Start: July 1, 2020
• Primary Completion: January 1, 2024
• Study Completion: January 1, 2025
• Last Updated: June 26, 2020

Record last verified: 2020-06

Data Sharing

• IPD Sharing: Will not share